AU Patent

AU2009222613B2 — N3 alkylated benzimidazole derivatives as MEK inhibitors

Assigned to AstraZeneca AB · Expires 2011-06-16 · 15y expired

What this patent protects

Patent listed against selumetinib-sulfate.

Drugs covered by this patent

selumetinib-sulfate (SELUMETINIB SULFATE)

Patent Metadata

Patent number: AU2009222613B2
Jurisdiction: AU
Classification: —
Expires: 2011-06-16
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.